Interim results for the six months ended June 30, 2026

Biodexa reported a 1H26 net loss of £1.84 million and operating cash burn of £4.61 million, leaving £3.23 million of cash at June 30, down from £8.53 million at year-end 2025. The company raised $3.5 million gross on July 1 but forecasts it will require additional financing in Q4 2026, creating a material going-concern uncertainty and likely dilution risk despite $26.08 million remaining under its ELOC. Operationally, its Phase 3 Serenta trial in FAP reached 92 of 168 planned patients, while MTX240 was in-licensed for GIST and is being prepared for Phase 1 restart.

Analysis

BDRX is a financing-security rather than a clinical-security over the next 1-3 months. The reported operating loss understates economic burn because a large non-cash derivative revaluation gain followed the share-price decline; cash consumption and the stated need for another raise in 4Q26 are the relevant valuation inputs. The ELOC, recent discounted financing, and multi-year warrant stack create persistent supply into any liquidity-driven rally, while a potential Nasdaq market-value deficiency could further impair access to capital and force a reverse-merger or asset-sale outcome.

The FAP program is the only near-term asset capable of changing financing terms, but enrollment progress is not equivalent to a de-risking efficacy event: its event-driven endpoint makes timing and eventual power sensitive to progression/surgery rates. Grant reimbursement lowers the nominal trial cost but does not eliminate matching-fund needs, so accelerated execution can paradoxically bring forward the financing requirement. MTX240 has mechanistic optionality in refractory GIST, yet manufacturing, IND preparation, and a first meaningful efficacy signal are likely a 12-18 month proposition—well beyond current funding visibility.

The contrarian case is that an independently strong NMIBC readout in 4Q26 could create a short-lived rerating and improve partnering leverage, while a strategic transaction could monetize the Nasdaq listing. Neither outcome solves the dilution math absent non-dilutive capital or a partner paying meaningful upfront consideration. PFE has no material earnings sensitivity to a reformulated legacy sirolimus program, and NDAQ exposure is limited to listing-fee economics; neither is a usable sympathy trade.

Key Decisions for Investors

• Avoid new long exposure in BDRX ahead of the expected 4Q26 financing window; treat any rally without a financing solution as an opportunity to reduce exposure, given ELOC and warrant-related share supply.
• For mandates able to source reliable borrow, consider a small tactical BDRX short only after liquidity-driven rallies toward or above the $2.85 warrant exercise reference; cover on confirmed non-dilutive partnership funding or a credible strategic transaction. Borrow availability and hard-to-borrow fees are required before implementation.
• Monitor the 4Q26 NMIBC data release as an event alert, not a pre-readout long: require disclosure of relapse-free-survival effect size, durability, and safety before assigning value. A statistically persuasive result could produce a 1-5 day squeeze but remains insufficient to fund the broader pipeline.
• Set a hard thesis reversal trigger on evidence that cash runway extends beyond 2Q27 without material dilution—e.g., a partner upfront payment or grant expansion—or on withdrawal/avoidance of Nasdaq compliance risk. Absent this, valuation should be anchored to expected financing dilution rather than pipeline NPV.